Approximately 400 million people globally and between 25 million to 30 million individuals in the United States live with a rare disease. These conditions often remain overlooked despite their widespread impact. Notably, half of those affected are children, and about one-third of these young patients die before reaching the age of five.

Rare diseases are generally defined as conditions affecting a small percentage of the population, but collectively they represent a significant public health challenge. The broad spectrum of rare diseases includes genetic disorders, rare cancers, and various chronic illnesses that often lack effective treatments or cures. This scarcity of options frequently stems from limited research, low commercial incentives for drug development, and challenges in diagnosis.

Efforts to address rare diseases include advocacy by patient groups, increased funding for research, and policy measures aimed at encouraging pharmaceutical companies to develop orphan drugs—medicines specifically targeting rare conditions. Despite these initiatives, many rare diseases remain underdiagnosed and undertreated, underscoring the need for further investment and awareness.

Experts emphasize that early diagnosis and intervention are crucial, especially for pediatric patients, to improve outcomes and quality of life. Advances in genetics and personalized medicine offer new hope, but comprehensive strategies involving healthcare providers, researchers, policymakers, and patient communities are essential to tackle the complexities of rare diseases worldwide.